Actively-treated patients treated for four weeks were able to read 13.5 more letters on an eye chart ... showing the tell-tale prostate-specific membrane antigen (PSMA). This is for men with ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Dsicover a recent study that compared Stockholm3 with other established biomarkers for prostate cancer screening. Learn more.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...

In 2021, just over a third of men ages 55 to 69 had had a PSA (prostate-specific antigen) blood test to check for prostate cancer in the past year. That ...

Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with NUBEQA ® ...

Nationally implemented screening programs that measure prostate-specific antigen (PSA) levels in the blood could offer men earlier access to treatment, improving their chances of a cure and ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Screening can involve testing for high levels of prostate-specific antigen (PSA) in the blood. However, it is worth noting that high levels of PSA can stem from noncancerous causes. A doctor can ...